BRUSSELS Feb 13 Belgian biotech firm Ablynx
said a clinical study of its rheumatoid arthritis drug
ALX-0061 showed promising results and it was now considering how
to further develop the drug, including a partnership deal with a
"We are now investigating the various possibilities through
which we can progress the development of ALX-0061, including
discussions with potential partners and other paths which will
allow us to maximise the value of this asset," Chief Executive
Edwin Moses said in a statement on Wednesday.
Ablynx had carried out the study on 37 patients over the
course of 24 weeks and said the drug was well-tolerated and
showed positive results.
(Reporting by Robert-Jan Bartunek; editing by Philip